Cargando…

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016

BACKGROUND: Oncotype DX® (ODX) is used to assess risk of disease recurrence in hormone receptor positive, HER2-negative breast cancer and to guide decisions regarding adjuvant chemotherapy. Little is known about how physician factors impact treatment decisions. The purpose of this study was to exami...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwedhelm, Thomas M., Rees, Judy R., Onega, Tracy, Zipkin, Ronnie J., Schaefer, Andrew, Celaya, Maria O., Moen, Erika L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650301/
https://www.ncbi.nlm.nih.gov/pubmed/32883270
http://dx.doi.org/10.1186/s12885-020-07355-6
_version_ 1783607486074322944
author Schwedhelm, Thomas M.
Rees, Judy R.
Onega, Tracy
Zipkin, Ronnie J.
Schaefer, Andrew
Celaya, Maria O.
Moen, Erika L.
author_facet Schwedhelm, Thomas M.
Rees, Judy R.
Onega, Tracy
Zipkin, Ronnie J.
Schaefer, Andrew
Celaya, Maria O.
Moen, Erika L.
author_sort Schwedhelm, Thomas M.
collection PubMed
description BACKGROUND: Oncotype DX® (ODX) is used to assess risk of disease recurrence in hormone receptor positive, HER2-negative breast cancer and to guide decisions regarding adjuvant chemotherapy. Little is known about how physician factors impact treatment decisions. The purpose of this study was to examine patient and physician factors associated with ODX testing and adjuvant chemotherapy for breast cancer patients in New Hampshire. METHODS: We examined New Hampshire State Cancer Registry data on 5630 female breast cancer patients diagnosed from 2010 to 2016. We performed unadjusted and adjusted hierarchical logistic regression to identify factors associated with a patient’s receipt of ODX, being recommended and receiving chemotherapy, and refusing chemotherapy. We calculated intraclass correlation coefficients (ICCs) to examine the proportion of variance in clinical decisions explained by between-physician and between-hospital variation. RESULTS: Over the study period, 1512 breast cancer patients received ODX. After adjustment for patient and tumor characteristics, we found that patients seen by a male medical oncologist were less likely to be recommended chemotherapy following ODX (OR = 0.50 (95% CI = 0.34–0.74), p < 0.01). Medical oncologists with more clinical experience (reference: less than 10 years) were more likely to recommend chemotherapy (20–29 years: OR = 4.05 (95% CI = 1.57–10.43), p < 0.01; > 29 years: OR = 4.48 (95% CI = 1.68–11.95), p < 0.01). A substantial amount of the variation in receiving chemotherapy was due to variation between physicians, particularly among low risk patients (ICC = 0.33). CONCLUSIONS: In addition to patient clinicopathologic characteristics, physician gender and clinical experience were associated with chemotherapy treatment following ODX testing. The significant variation between physicians indicates the potential for interventions to reduce variation in care.
format Online
Article
Text
id pubmed-7650301
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76503012020-11-09 Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016 Schwedhelm, Thomas M. Rees, Judy R. Onega, Tracy Zipkin, Ronnie J. Schaefer, Andrew Celaya, Maria O. Moen, Erika L. BMC Cancer Research Article BACKGROUND: Oncotype DX® (ODX) is used to assess risk of disease recurrence in hormone receptor positive, HER2-negative breast cancer and to guide decisions regarding adjuvant chemotherapy. Little is known about how physician factors impact treatment decisions. The purpose of this study was to examine patient and physician factors associated with ODX testing and adjuvant chemotherapy for breast cancer patients in New Hampshire. METHODS: We examined New Hampshire State Cancer Registry data on 5630 female breast cancer patients diagnosed from 2010 to 2016. We performed unadjusted and adjusted hierarchical logistic regression to identify factors associated with a patient’s receipt of ODX, being recommended and receiving chemotherapy, and refusing chemotherapy. We calculated intraclass correlation coefficients (ICCs) to examine the proportion of variance in clinical decisions explained by between-physician and between-hospital variation. RESULTS: Over the study period, 1512 breast cancer patients received ODX. After adjustment for patient and tumor characteristics, we found that patients seen by a male medical oncologist were less likely to be recommended chemotherapy following ODX (OR = 0.50 (95% CI = 0.34–0.74), p < 0.01). Medical oncologists with more clinical experience (reference: less than 10 years) were more likely to recommend chemotherapy (20–29 years: OR = 4.05 (95% CI = 1.57–10.43), p < 0.01; > 29 years: OR = 4.48 (95% CI = 1.68–11.95), p < 0.01). A substantial amount of the variation in receiving chemotherapy was due to variation between physicians, particularly among low risk patients (ICC = 0.33). CONCLUSIONS: In addition to patient clinicopathologic characteristics, physician gender and clinical experience were associated with chemotherapy treatment following ODX testing. The significant variation between physicians indicates the potential for interventions to reduce variation in care. BioMed Central 2020-09-03 /pmc/articles/PMC7650301/ /pubmed/32883270 http://dx.doi.org/10.1186/s12885-020-07355-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Schwedhelm, Thomas M.
Rees, Judy R.
Onega, Tracy
Zipkin, Ronnie J.
Schaefer, Andrew
Celaya, Maria O.
Moen, Erika L.
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
title Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
title_full Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
title_fullStr Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
title_full_unstemmed Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
title_short Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
title_sort patient and physician factors associated with oncotype dx and adjuvant chemotherapy utilization for breast cancer patients in new hampshire, 2010–2016
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650301/
https://www.ncbi.nlm.nih.gov/pubmed/32883270
http://dx.doi.org/10.1186/s12885-020-07355-6
work_keys_str_mv AT schwedhelmthomasm patientandphysicianfactorsassociatedwithoncotypedxandadjuvantchemotherapyutilizationforbreastcancerpatientsinnewhampshire20102016
AT reesjudyr patientandphysicianfactorsassociatedwithoncotypedxandadjuvantchemotherapyutilizationforbreastcancerpatientsinnewhampshire20102016
AT onegatracy patientandphysicianfactorsassociatedwithoncotypedxandadjuvantchemotherapyutilizationforbreastcancerpatientsinnewhampshire20102016
AT zipkinronniej patientandphysicianfactorsassociatedwithoncotypedxandadjuvantchemotherapyutilizationforbreastcancerpatientsinnewhampshire20102016
AT schaeferandrew patientandphysicianfactorsassociatedwithoncotypedxandadjuvantchemotherapyutilizationforbreastcancerpatientsinnewhampshire20102016
AT celayamariao patientandphysicianfactorsassociatedwithoncotypedxandadjuvantchemotherapyutilizationforbreastcancerpatientsinnewhampshire20102016
AT moenerikal patientandphysicianfactorsassociatedwithoncotypedxandadjuvantchemotherapyutilizationforbreastcancerpatientsinnewhampshire20102016